0001193125-17-027586.txt : 20170306 0001193125-17-027586.hdr.sgml : 20170306 20170201170632 ACCESSION NUMBER: 0001193125-17-027586 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARROWHEAD PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000879407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460408024 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 225 SOUTH LAKE AVENUE STREET 2: SUITE 1050 CITY: PASADENA STATE: CA ZIP: 91101 BUSINESS PHONE: 626-304-3400 MAIL ADDRESS: STREET 1: 225 SOUTH LAKE AVENUE STREET 2: SUITE 1050 CITY: PASADENA STATE: CA ZIP: 91101 FORMER COMPANY: FORMER CONFORMED NAME: ARROWHEAD RESEARCH CORP DATE OF NAME CHANGE: 20040112 FORMER COMPANY: FORMER CONFORMED NAME: INTERACTIVE GROUP INC DATE OF NAME CHANGE: 20020509 FORMER COMPANY: FORMER CONFORMED NAME: INTERACTIVE INC DATE OF NAME CHANGE: 19940224 CORRESP 1 filename1.htm CORRESP

[Letterhead of Arrowhead Pharmaceuticals, Inc.]

February 1, 2017

VIA EDGAR AND FACSIMILE

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

Attention: Mr. Johnny Gharib

 

  Re: Arrowhead Pharmaceuticals, Inc.
       Registration Statement on Form S-3 (File No. 333-214311)

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the “Company”), respectfully requests the acceleration of the effectiveness of the above-referenced Registration Statement (the “Filing”), so as to become effective at 5:00 p.m. (EST) on February 3, 2017, or as soon as possible thereafter.

The Company hereby acknowledges that:

 

  •   should the United States Securities and Exchange Commission (the “Commission”) or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the Filing effective, it does not foreclose the Commission from taking any action with respect to the Filing;

 

  •   the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Filing; and

 

  •   the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

We request that we be notified of the effectiveness of the Filing by telephone call to Ryan Murr of Gibson, Dunn & Crutcher LLP, at (415) 393-8373.

Mr. Johnny Gharib

Securities and Exchange Commission

Page 2

 

Please do not hesitate to contact the undersigned at (626) 304-3400, or Ryan Murr of Gibson, Dunn & Crutcher LLP at (415) 393-8373 with any questions or comments with respect to this letter.

 

Very truly yours,
Arrowhead Pharmaceuticals, Inc.
By:   /s/ Christopher Anzalone
  Dr. Christopher Anzalone
  President and Chief Executive Officer

 

 

cc: Ryan Murr, Gibson, Dunn & Crutcher LLP